Compare AstraZeneca plc (AZN) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares MSCI South Korea ETF — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while iShares MSCI South Korea ETF trades at $170.96. The key difference: AstraZeneca plc pays a 1.92% dividend while iShares MSCI South Korea ETF pays none, and iShares MSCI South Korea ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | EWY | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $219.20 |
52-Week Low | $137.44 | $70.65 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EWY, the iShares MSCI South Korea ETF, trades at $168.08, down 8.41% over 24 hours amid a bearish technical signal. The ETF is heavily concentrated in Samsung and SK Hynix, exposing it to volatility in AI-driven semiconductor demand. Recent news highlights South Korean market turbulence, with the Kospi Index experiencing sharp declines and recoveries tied to chip stock performance. Key support lies at $162, with resistance at $171. Financial ratios are unavailable in the provided data, limiting fundamental clarity.
The outlook for EWY hinges on semiconductor cycle dynamics and foreign investor sentiment. Opportunities exist if AI memory demand rebounds, but risks include high concentration in two stocks, global tech volatility, and macroeconomic pressures. The bearish technical trend and neutral oscillators suggest cautious near-term momentum, requiring monitoring of earnings from top holdings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
